EQT Fund Management S.a r.l.

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), EQT Fund Management S.a r.l. reported 5 stock positions worth $1.0 billion. Its top holding was Waystar (WAY) at 58.8% of the portfolio, followed by Oculis (OCS, 15.4%) and Evommune (EVMN, 11.1%). Compared with Q4 2025, it opened 1 new position. The biggest buy was a new position in Agomab Therapeutics (AGMB).

Most Recent 13F
Q2 2026
Location
LUXEMBOURG, N4
CIK
0001834239
Portfolio Value
$1.0B (Q1 2026)
SEC Filing
0001193125-26-224227 ↗ filed May 14, 2026

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q3 2025: $1.9B Q3 2025 Q4 2025: $1.1B Q4 2025 Q1 2026: $1.0B $1.0B Q1 2026 Q2 2026: $862.6M Q2 2026

Holdings 5 stocks · $1.0B
WAY Waystar Holding Corp. 58.77% 24,879,437 $599.8M No change
OCS Oculis Holding AG 15.37% 5,900,294 $156.9M No change
EVMN Evommune Inc. 11.10% 4,929,633 $113.3M No change
PHVS Pharvaris NV 9.48% 3,424,609 $96.7M No change
AGMB Agomab Therapeutics NV 5.28% 5,141,992 $53.9M New

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
AGMB Agomab Therapeutics NV New 5.28% +5.28

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 5$862.6MWAY, PHVS, OCS, EVMN, AGMB
Q1 2026 5$1.0BWAY, OCS, EVMN, PHVS, AGMB
Q4 2025 4$1.1BWAY, OCS, PHVS, EVMN
Q3 2025 4$1.9BWAY, KGS, OCS, PHVS